These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

140 related items for PubMed ID: 38906550

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Imatinib and M351-0056 enhance the function of VISTA and ameliorate the development of SLE via IFN-I and noncanonical NF-κB pathway.
    Yang L, Zhang T, Wang P, Chen W, Liu W, He X, Zhang Y, Jin S, Luo Z, Zhang Z, Wang X, Liu J.
    Cell Biol Toxicol; 2023 Dec; 39(6):3287-3304. PubMed ID: 37804401
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Interleukin 6 (IL-6) deficiency delays lupus nephritis in MRL-Faslpr mice: the IL-6 pathway as a new therapeutic target in treatment of autoimmune kidney disease in systemic lupus erythematosus.
    Cash H, Relle M, Menke J, Brochhausen C, Jones SA, Topley N, Galle PR, Schwarting A.
    J Rheumatol; 2010 Jan; 37(1):60-70. PubMed ID: 19955044
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Therapeutic effects of the artemisinin analog SM934 on lupus-prone MRL/lpr mice via inhibition of TLR-triggered B-cell activation and plasma cell formation.
    Wu Y, He S, Bai B, Zhang L, Xue L, Lin Z, Yang X, Zhu F, He P, Tang W, Zuo J.
    Cell Mol Immunol; 2016 May; 13(3):379-90. PubMed ID: 25942599
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Intermittent Fasting Aggravates Lupus Nephritis through Increasing Survival and Autophagy of Antibody Secreting Cells in MRL/lpr Mice.
    Hong SM, Lee J, Jang SG, Song Y, Kim M, Lee J, Cho ML, Kwok SK, Park SH.
    Int J Mol Sci; 2020 Nov 11; 21(22):. PubMed ID: 33187196
    [Abstract] [Full Text] [Related]

  • 34. IgG4 Autoantibodies Attenuate Systemic Lupus Erythematosus Progression by Suppressing Complement Consumption and Inflammatory Cytokine Production.
    Pan Q, Xiao H, Shi L, He Y, Cai J, Wu J, Li A, Ye L, Yang C, Liu HF.
    Front Immunol; 2020 Nov 11; 11():1047. PubMed ID: 32625200
    [Abstract] [Full Text] [Related]

  • 35. Blockade of OX40/OX40L signaling using anti-OX40L alleviates murine lupus nephritis.
    Zhao J, Li L, Feng X, Yin H, Fan X, Gao C, Zhao M, Lu Q.
    Eur J Immunol; 2024 Aug 11; 54(8):e2350915. PubMed ID: 38798163
    [Abstract] [Full Text] [Related]

  • 36. Anti-IL-12/23 p40 antibody attenuates chronic graft-versus-host disease with lupus nephritis via inhibiting Tfh cell in mice.
    Gao Y, Zeng Y, Xue W, Chen Y, Li Q, Bian Z, Tang L, Tang T, Chen C, Gao X, Guo W.
    Biomed Pharmacother; 2020 Sep 11; 129():110396. PubMed ID: 32580046
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Annexin A1 as a target for managing murine pristane-induced systemic lupus erythematosus.
    Mihaylova N, Bradyanova S, Chipinski P, Herbáth M, Chausheva S, Kyurkchiev D, Prechl J, Tchorbanov AI.
    Autoimmunity; 2017 Jun 11; 50(4):257-268. PubMed ID: 28300427
    [Abstract] [Full Text] [Related]

  • 39. Rapamycin reverses the senescent phenotype and improves immunoregulation of mesenchymal stem cells from MRL/lpr mice and systemic lupus erythematosus patients through inhibition of the mTOR signaling pathway.
    Gu Z, Tan W, Ji J, Feng G, Meng Y, Da Z, Guo G, Xia Y, Zhu X, Shi G, Cheng C.
    Aging (Albany NY); 2016 May 11; 8(5):1102-14. PubMed ID: 27048648
    [Abstract] [Full Text] [Related]

  • 40. Tetra-arsenic tetra-sulfide ameliorates lupus syndromes by inhibiting IL-17 producing double negative T cells.
    Zhao Y, Mu Z, Cai L, Liu X, Jia J, Zhang J.
    Dermatol Ther; 2019 Jul 11; 32(4):e12849. PubMed ID: 30707471
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 7.